COVID-19 trials registries data warehouse

http://www.chictr.org.cn/showproj.aspx?proj=49229

Xue Zhigang

xuezg@tongji.edu.cn

2020-02-24

Not recruiting

RCT

Randomized

Parallel

Not reported

single-center

Treatment

1. Aged 18-60 years old, 2. Patients with clinical symptoms, signs, auxiliary detection combined with 1 or more nucleic acid test to confirm the diagnosis of new coronavirus pneumonia, 3. Voluntarily sign the informed consent to comply with the requirements of the program.

1. History of tumor, 2. Vascular embolism and pulmonary hypertension, 3. Suspected or established history of alcohol, drug or drug abuse, 4. Female patients of child-bearing age who are pregnant, breast-feeding or have a recent family planning, 5. Patients who have participated in or are participating in other drug trials within one month, 6. Patients considered unfit to participate in this clinical trial.

2

Hunan yuanpin Cell Biotechnology Co.; Ltd

18

70

China

Mild/moderate disease at enrollment

2: Mild/moderate disease at enrollment

60

pulmonary function;Novel coronavirus pneumonic nucleic acid test;

| Declared number of arm (2.0) differs from found arms (3.0)

Phase 0

[{"arm_notes": "", "treatment_id": 787, "treatment_name": "Mesenchymal stem cells", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]